CDEK
← All drugs Report issue

epothilone

Small moleculeexperimental

Epothilones are a class of potential cancer drugs. Like taxanes, they prevent cancer cells from dividing by interfering with tubulin, but in early trials, epothilones have better efficacy and milder adverse effects than taxanes. — Wikipedia

Clinical trial activity

39 trials · 19 clinical orgs · 0 marketing orgs

Phase 1
17
Phase 2
26
Phase 3
2
Phase 4
0

Earliest trial started Feb 1, 2001 (NCT00035516)

Timeline

2000s

  1. Jan 1, 2001

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2001

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2005

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Mol. weight
507.69 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 12,13-desoxyepothilone b
  • depob cpd
  • desoxyepothilone b
  • epo906
  • epo906
  • epo906
  • epo b
  • epo b
  • epothilon b
  • epothilon d
  • epothilone
  • epothilone
  • (−)-epothilone b
  • (−)-epothilone b
  • epothilone b
  • epothilone b
  • epothilone b
  • epothilone b
  • epothilone b, desoxy
  • epothilone d
  • epothiolone d
  • gnf-pf-193
  • gnf-pf-193
  • kos862
  • kos 862
  • kos-862
  • kos-862
  • kos-862
  • patupilone
  • patupilone
  • patupilone
  • patupilone
  • patupilone
  • utd1

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06683703Phase 2Dec 1, 2024Biostar
NCT05535413Phase 1/Phase 2 (Phase 2)Aug 1, 2022Central South University
NCT05398861Phase 2Jun 1, 2022Biostar, Henan Medical University, Qilu Pharmaceutical Co., Ltd.
NCT02253459Phase 3Aug 1, 2014Biostar, Chinese Academy of Medical Sciences
NCT00715013Phase 1/Phase 2 (Phase 2)Jul 1, 2008University of Zurich
NCT00442741Phase 1Jul 1, 2007Novartis
NCT00496600Phase 1Jul 1, 2007National Cancer Institute (NCI), Novartis, Rutgers University, University of Medicine and Dentistry of New Jersey
NCT00468260Phase 1May 1, 2007Novartis
NCT00448396Phase 1Mar 1, 2007Novartis
NCT00407251Phase 2Feb 1, 2007British Columbia Cancer Agency
NCT00450866Phase 2Jan 1, 2007Case Western Reserve University, National Cancer Institute (NCI), University of Rochester
NCT00420615Phase 1Dec 1, 2006Novartis
NCT00411528Phase 2Sep 1, 2006Novartis
NCT00412789Phase 1Aug 1, 2006Novartis
NCT00426582Phase 1Aug 1, 2006Novartis
NCT00426140Phase 1Aug 1, 2006Novartis
NCT00421044Phase 1May 1, 2006Novartis
NCT00273312Phase 2Jan 1, 2006Novartis
NCT00420524Phase 1Jan 1, 2006Novartis
NCT00219297Phase 2Nov 1, 2005Novartis
Showing 20 of 39 trials
Page 1 / 2

Organizations

Research & Development (19)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
NovartisFor profit252232001
National Cancer Institute (NCI)Government4022003
BiostarFor profit3222014
Bristol-Myers SquibbFor profit3322001
Cornell UniversityAcademic/Hospital2212003
British Columbia Cancer AgencyAcademic/Hospital1112007
Case Western Reserve UniversityAcademic/Hospital1112007
Central South UniversityAcademic/Hospital1112022
Chinese Academy of Medical SciencesAcademic/Hospital1012014
Henan Medical UniversityAcademic/Hospital1112022
Qilu Pharmaceutical Co., Ltd.For profit1012022
RocheFor profit1112004
R-PharmFor profit1112001
Rutgers UniversityAcademic/Hospital1012007
Thomas Jefferson UniversityAcademic/Hospital1112004
University of Medicine and Dentistry of New JerseyAcademic/Hospital1112007
University of RochesterAcademic/Hospital1012007
University of Southern CaliforniaAcademic/Hospital1112004
University of ZurichAcademic/Hospital1112008
19 organizations
Page 1 / 1